No products in the cart.
Pre-made Petosemtamab benchmark antibody ( Bispecific mAb, anti-EGFR;LGR5 therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;FEX/GPR49/GPR67/GRP49/HG38 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-440
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Petosemtamab biosimilar, Bispecific mAb, Anti-EGFR;LGR5 Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;FEX/GPR49/GPR67/GRP49/HG38 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Petosemtamab (also known as MCLA 158) is a bispecific, full length human IgG antibody being developed by Merus, for the treatment of solid tumours including.
| Products Name (INN Index) | Pre-Made Petosemtamab biosimilar, Bispecific mAb, Anti-EGFR;LGR5 Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;FEX/GPR49/GPR67/GRP49/HG38 therapeutic antibody |
|---|---|
| INN Name | Petosemtamab |
| Target | EGFR,LGR5 |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Merus |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Colorectal cancer,Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | EGFR,LGR5 |
| Package |
Previous slide
Next slide
